Log In
BCIQ
Print this Print this
 

SEL-212

  Manage Alerts
Collapse Summary General Information
Company Selecta Biosciences Inc.
DescriptionNon-immunogenic therapy comprising pegsiticase (SEL-037), a pegylated uricase, co-administered with SVP-Rapamycin (SEL-110), a nanoparticle encapsulating the immunomodulator rapamycin
Molecular Target Uric acid
Mechanism of Action 
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase II
Standard IndicationHyperuricemia / gout
Indication DetailsTreat chronic gout; Treat refractory and tophaceous gout
Regulatory Designation
Partner3SBio Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today